High-Density Lipoprotein-Targeted Therapies for Heart Failure
The main and common constituents of high-density lipoproteins (HDLs) are apolipoprotein A-I, cholesterol, and phospholipids. Biochemical heterogeneity of HDL particles is based on the variable presence of one or more representatives of at least 180 proteins, 200 lipid species, and 20 micro RNAs. HDL...
Main Authors: | Mudit Mishra, Bart De Geest |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/8/12/620 |
Similar Items
-
Role of Oxidative Stress in Heart Failure: Insights from Gene Transfer Studies
by: Bart De Geest, et al.
Published: (2021-11-01) -
Increased Remnant Lipoproteins in Apo E Deficient Mice Induce Coronary Atherosclerosis following Transverse Aortic Constriction and Aggravate the Development of Pressure Overload-Induced Cardiac Hypertrophy and Heart Failure
by: Ilayaraja Muthuramu, et al.
Published: (2022-07-01) -
High-Density Lipoprotein and Heart Failure
by: Liyun Xing, et al.
Published: (2023-11-01) -
Selective HDL-Raising Human Apo A-I Gene Therapy Counteracts Cardiac Hypertrophy, Reduces Myocardial Fibrosis, and Improves Cardiac Function in Mice with Chronic Pressure Overload
by: Ruhul Amin, et al.
Published: (2017-09-01) -
Heart Failure, Left Ventricular Remodeling, and Circulating Nitric Oxide Metabolites
by: Julio A. Chirinos, et al.
Published: (2016-10-01)